AstraZeneca Reports Strong Q2 Growth

AstraZeneca PLC has announced a significant increase in its second-quarter revenue for the fiscal year 2025, marking a 12% annual rise to $14.5 billion. This growth is attributed to an 11% year-on-year increase in product sales, which reached $13.8 billion. Furthermore, the company's earnings per share (EPS) soared by 27% to $1.58.

First Half Performance Highlights

The first half of the year also showcased robust performance, with total revenue climbing by 9% to $28 billion and product sales growing by 8% to $26.7 billion. The reported EPS for this period was $3.46, reflecting a 31% increase.

Strategic Investments for Future Growth

"As we embark on our next growth phase, we are committing $50 billion to expand our presence in the US, including a historic manufacturing investment in Virginia," stated CEO Pascal Soriot. He emphasized the company's belief in its innovative medicines to revolutionize global health and achieve its ambitious goal of $80 billion in revenue by 2030.